Peptide vaccines are in development as potential therapies for many major conditions, including chronic viral infections, allergies, cancer, Alzheimer’s disease, diabetes, hypertension, obesity, and rheumatoid arthritis. The therapeutic vaccines are known to induce neutralizing antibodies against self-molecules and have been clinically tested.
Active immunotherapy has been the most extensively studied approach in Aβ-targeted therapy. To improve the immunogenicity and reduce the adverse event, in the past decade progress of active immunotherapy has been made both in the selection of B cell epitope and the carrier protein. Progress made in peptide-based vaccinations to induce antibody has invigorated the search for vaccine modalities.
Peptide vaccine Active immunotherapy Carrier protein B cell epitope
This is a preview of subscription content, log in to check access.
Cease KB et al (1987) Helper T-cell antigenic site identification in the acquired immunodeficiency syndrome virus gp120 envelope protein and induction of immunity in mice to the native protein using a 16-residue synthetic peptide. Proc Natl Acad Sci U S A 84:4249–4253CrossRefGoogle Scholar
Davtyan H et al (2013) Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer’s disease: prelude to a clinical trial. J Neurosci 33:4923–4934CrossRefGoogle Scholar
Gilman S et al (2005) Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64:1553–1562CrossRefGoogle Scholar
Hernandez I et al (2018) Pricing of monoclonal antibody therapies: higher if used for cancer? Am J Manag Care 24:109–112PubMedGoogle Scholar
Nakagami H, Morishita R (2018) Recent advances in therapeutic vaccines to treat hypertension. Hypertension 72:1031–1036CrossRefGoogle Scholar
Nandy A, Basak SC (2016) A brief review of computer-assisted approaches to rational design of peptide vaccines. Int J Mol Sci 17CrossRefGoogle Scholar
Wang CY, Walfield AM (2005) Site-specific peptide vaccines for immunotherapy and immunization against chronic diseases, cancer, infectious diseases, and for veterinary applications. Vaccine 23:2049–2056CrossRefGoogle Scholar
Wiessner C et al (2011) The second-generation active Abeta immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J Neurosci 31:9323–9331CrossRefGoogle Scholar
Winblad B et al (2012) Safety, tolerability, and antibody response of active Abeta immunotherapy with CAD106 in patients with Alzheimer’s disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol 11:597–604CrossRefGoogle Scholar